| Title |
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
|
|---|---|
| Published in |
Journal of Blood Medicine, June 2015
|
| DOI | 10.2147/jbm.s72463 |
| Pubmed ID | |
| Authors |
Antoine N Saliba, Afif R Harb, Ali T Taher |
| Abstract |
Transfusional iron overload is a major target in the care of patients with transfusion-dependent thalassemia (TDT) and other refractory anemias. Iron accumulates in the liver, heart, and endocrine organs leading to a wide array of complications. In this review, we summarize the characteristics of the approved iron chelators, deferoxamine, deferiprone, and deferasirox, and the evidence behind the use of each, as monotherapy or as part of combination therapy. We also review the different guidelines on iron chelation in TDT. This review also discusses future prospects and directions in the treatment of transfusional iron overload in TDT whether through innovation in chelation or other therapies, such as novel agents that improve transfusion dependence. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 193 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | <1% |
| Unknown | 192 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 41 | 21% |
| Other | 19 | 10% |
| Student > Ph. D. Student | 16 | 8% |
| Student > Postgraduate | 15 | 8% |
| Student > Master | 15 | 8% |
| Other | 27 | 14% |
| Unknown | 60 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 69 | 36% |
| Biochemistry, Genetics and Molecular Biology | 15 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
| Nursing and Health Professions | 8 | 4% |
| Agricultural and Biological Sciences | 7 | 4% |
| Other | 20 | 10% |
| Unknown | 64 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2021.
All research outputs
#5,340,716
of 25,584,565 outputs
Outputs from Journal of Blood Medicine
#63
of 318 outputs
Outputs of similar age
#61,787
of 281,752 outputs
Outputs of similar age from Journal of Blood Medicine
#2
of 8 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 318 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,752 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.